AstraZeneca's IMFINZI Combo Dramatically Cuts Bladder Cancer Recurrence and Death

A groundbreaking new treatment for muscle-invasive bladder cancer just hit the headlines, with AstraZeneca IMFINZI (durvalumab) in combination with neoadjuvant enfortumab vedotin dramatically cutting the risk of recurrence by 49% and death by 42%. These impressive results from the VOLGA Phase III trial, unveiled at the ESMO Congress 2026, offer a significant new hope for patients who can't undergo standard cisplatin-based chemotherapy or have chosen not to. This breakthrough arrives in a landscape where bladder cancer remains a major challenge, especially for patients with muscle-invasive disease who often face high recurrence rates even after surgery. While a similar combination therapy of enfortumab vedotin with Merck's Keytruda (pembrolizumab) received FDA approval in November 2025, AstraZeneca regimen aims to differentiate itself by delivering enfortumab vedotin only before surgery, potentially offering a more patient-friendly approach. Experts at ESMO are keenly watching how this new data will reshape the standard of care for this aggressive cancer. Looking ahead, AstraZeneca has already submitted a supplemental Biologics License Application (sBLA) to the U.S. FDA, which has been granted Priority Review, with a decision expected in the fourth quarter of 2026. If approved, this combination could become a crucial perioperative treatment option, potentially shifting clinical practice and improving long-term outcomes for thousands of patients annually. The oncology community will be eagerly awaiting regulatory decisions and further real-world data on this promising therapy.